We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sanofi: Information concerning the total number of voting rights and shares - October 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II...
Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée La FDA a accepté l’examen de la sBLA pour le Dupixent dans le...
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive...
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria...
Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe Sarclisa : approbation...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Sarclisa recommended for EU approval by the CHMP to treat...
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination...
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Dupixent approved in the EU as the first and only medicine for young...
Communiqué de presse : Dupixent, premier et seul médicament approuvé dans l’UE pour le traitement de l’œsophagite à éosinophiles du jeune enfant Dupixent, premier et seul médicament approuvé dans...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.95 | -3.15981148243 | 93.36 | 94.4 | 90.17 | 1814274 | 91.84798315 | DE |
4 | -8 | -8.129255157 | 98.41 | 101.9 | 90.17 | 1619800 | 95.67021175 | DE |
12 | -10.23 | -10.1649443561 | 100.64 | 106.14 | 90.17 | 1549285 | 100.17713939 | DE |
26 | 0.84 | 0.937814000223 | 89.57 | 106.14 | 85.94 | 1476531 | 96.02560974 | DE |
52 | 5.41 | 6.36470588235 | 85 | 106.14 | 83.28 | 1446217 | 92.79867252 | DE |
156 | 1.02 | 1.14106723347 | 89.39 | 106.66 | 76.45 | 1758300 | 92.46885427 | DE |
260 | 8.15 | 9.90761001702 | 82.26 | 106.66 | 67.65 | 1951544 | 89.31660651 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions